BA
IDXG

Ballew Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Ballew Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,200
Closed -$11K – 528
2018
Q2 		$11K Buy
+1,200
New +$10.6K 0.01% 298

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Ballew Advisors's IDXG Position: Q3 2018 in Review

Ballew Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2018, closing a stake of 1,200 shares — an estimated $11K sold.

Ballew Advisors first reported a position in IDXG in Q2 2018 and held it in 1 quarter. The position peaked at $11K in Q2 2018. 18 funds tracked by Wall St. Rank hold IDXG as of Q3 2018.

  • Ballew Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Ballew Advisors sold 1,200 Interpace Biosciences, Inc. Common Stock shares in Q3 2018, an estimated $11K.
  • Ballew Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Ballew Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $11K in Q2 2018.
  • 18 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2018.

Based on Ballew Advisors's 13F filing for Q3 2018, filed 30 Oct 2018.